176 related articles for article (PubMed ID: 20686816)
1. Nutlin-1 strengthened anti-proliferation and differentiation-inducing activity of ATRA in ATRA-treated p-glycoprotein deregulated human myelocytic leukemia cells.
Zhang L; Yan Y; Zhu D; Yang W; Wang W; Hu Y; Yang B; He Q
Invest New Drugs; 2012 Feb; 30(1):37-47. PubMed ID: 20686816
[TBL] [Abstract][Full Text] [Related]
2. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.
Gianni' M; Kalaç Y; Ponzanelli I; Rambaldi A; Terao M; Garattini E
Blood; 2001 May; 97(10):3234-43. PubMed ID: 11342454
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
[TBL] [Abstract][Full Text] [Related]
5. The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.
Secchiero P; Zerbinati C; Melloni E; Milani D; Campioni D; Fadda R; Tiribelli M; Zauli G
Neoplasia; 2007 Oct; 9(10):853-61. PubMed ID: 17971905
[TBL] [Abstract][Full Text] [Related]
6. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
8. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro.
Shiohara M; Dawson MI; Hobbs PD; Sawai N; Higuchi T; Koike K; Komiyama A; Koeffler HP
Blood; 1999 Mar; 93(6):2057-66. PubMed ID: 10068679
[TBL] [Abstract][Full Text] [Related]
9. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.
Chen L; Zhao Y; Halliday GC; Berry P; Rousseau RF; Middleton SA; Nichols GL; Del Bello F; Piergentili A; Newell DR; Lunec J; Tweddle DA
Br J Cancer; 2014 Aug; 111(4):716-25. PubMed ID: 24921920
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
[TBL] [Abstract][Full Text] [Related]
11. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P
J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A
Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250
[TBL] [Abstract][Full Text] [Related]
14. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
[TBL] [Abstract][Full Text] [Related]
15. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP
Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549
[TBL] [Abstract][Full Text] [Related]
16. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
[TBL] [Abstract][Full Text] [Related]
17. Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells.
Tokura Y; Shikami M; Miwa H; Watarai M; Sugamura K; Wakabayashi M; Satoh A; Imamura A; Mihara H; Katoh Y; Kita K; Nitta M
Leuk Res; 2002 Jan; 26(1):29-36. PubMed ID: 11734301
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
19. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
[TBL] [Abstract][Full Text] [Related]
20. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
